| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wound Healing | 25 | 2023 | 749 | 5.630 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 23 | 2024 | 386 | 4.190 |
Why?
|
| Interleukin-10 | 12 | 2023 | 483 | 3.720 |
Why?
|
| Biomedical Research | 13 | 2023 | 801 | 3.480 |
Why?
|
| Hyaluronic Acid | 11 | 2021 | 151 | 2.770 |
Why?
|
| Cicatrix | 6 | 2023 | 187 | 2.590 |
Why?
|
| Surgeons | 9 | 2023 | 491 | 2.590 |
Why?
|
| Fetus | 10 | 2023 | 674 | 1.950 |
Why?
|
| Respiratory System Abnormalities | 8 | 2024 | 42 | 1.860 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2024 | 170 | 1.800 |
Why?
|
| Lung | 19 | 2024 | 3298 | 1.610 |
Why?
|
| Awards and Prizes | 3 | 2023 | 86 | 1.600 |
Why?
|
| Skin | 8 | 2023 | 1271 | 1.600 |
Why?
|
| Gene Transfer Techniques | 10 | 2015 | 804 | 1.580 |
Why?
|
| Neovascularization, Physiologic | 8 | 2022 | 346 | 1.550 |
Why?
|
| Fetoscopy | 12 | 2024 | 411 | 1.540 |
Why?
|
| Career Mobility | 3 | 2021 | 89 | 1.530 |
Why?
|
| Writing | 3 | 2021 | 104 | 1.530 |
Why?
|
| Extracorporeal Membrane Oxygenation | 8 | 2024 | 641 | 1.500 |
Why?
|
| Fibroblasts | 5 | 2020 | 1654 | 1.460 |
Why?
|
| Ultrasonography, Prenatal | 17 | 2024 | 923 | 1.460 |
Why?
|
| Wounds and Injuries | 6 | 2020 | 437 | 1.440 |
Why?
|
| Intestines | 3 | 2021 | 736 | 1.370 |
Why?
|
| Prenatal Diagnosis | 12 | 2024 | 610 | 1.350 |
Why?
|
| Extracellular Matrix | 8 | 2020 | 524 | 1.310 |
Why?
|
| Trachea | 9 | 2024 | 298 | 1.240 |
Why?
|
| Fetal Development | 3 | 2015 | 118 | 1.230 |
Why?
|
| Discrete Subaortic Stenosis | 2 | 2024 | 7 | 1.160 |
Why?
|
| Phenyl Ethers | 2 | 2024 | 9 | 1.160 |
Why?
|
| Research Support as Topic | 2 | 2021 | 120 | 1.140 |
Why?
|
| Mentors | 3 | 2021 | 210 | 1.130 |
Why?
|
| Infant, Newborn | 42 | 2024 | 8699 | 1.130 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2023 | 197 | 1.130 |
Why?
|
| Financing, Organized | 3 | 2022 | 21 | 1.120 |
Why?
|
| Pregnancy | 46 | 2024 | 8130 | 1.110 |
Why?
|
| Surgical Wound Infection | 2 | 2020 | 495 | 1.080 |
Why?
|
| Gestational Age | 10 | 2024 | 1173 | 1.040 |
Why?
|
| Hypertension, Pulmonary | 4 | 2024 | 464 | 1.030 |
Why?
|
| Bioprinting | 1 | 2024 | 9 | 0.980 |
Why?
|
| Hyaluronoglucosaminidase | 2 | 2021 | 44 | 0.950 |
Why?
|
| Gastroschisis | 2 | 2021 | 54 | 0.940 |
Why?
|
| Wound Infection | 4 | 2022 | 66 | 0.910 |
Why?
|
| Spheroids, Cellular | 1 | 2024 | 220 | 0.900 |
Why?
|
| Pediatrics | 4 | 2019 | 1186 | 0.900 |
Why?
|
| Hydrops Fetalis | 3 | 2020 | 75 | 0.900 |
Why?
|
| Fetal Therapies | 3 | 2018 | 74 | 0.900 |
Why?
|
| Dependovirus | 3 | 2013 | 142 | 0.880 |
Why?
|
| Genetic Therapy | 4 | 2015 | 1716 | 0.870 |
Why?
|
| General Surgery | 3 | 2019 | 333 | 0.850 |
Why?
|
| Bandages | 2 | 2020 | 75 | 0.840 |
Why?
|
| Teratoma | 7 | 2024 | 248 | 0.830 |
Why?
|
| Obstetric Labor, Premature | 1 | 2023 | 86 | 0.820 |
Why?
|
| Cystic Fibrosis | 3 | 2012 | 294 | 0.820 |
Why?
|
| Kidney | 3 | 2021 | 2121 | 0.790 |
Why?
|
| Dermis | 1 | 2021 | 63 | 0.770 |
Why?
|
| Pulmonary Fibrosis | 2 | 2020 | 175 | 0.770 |
Why?
|
| Budgets | 1 | 2021 | 24 | 0.770 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2015 | 631 | 0.760 |
Why?
|
| Lung Diseases | 6 | 2023 | 755 | 0.760 |
Why?
|
| Genetic Vectors | 5 | 2013 | 1857 | 0.750 |
Why?
|
| Molecular Weight | 3 | 2021 | 721 | 0.750 |
Why?
|
| Actins | 1 | 2024 | 602 | 0.750 |
Why?
|
| Perinatal Care | 2 | 2022 | 68 | 0.730 |
Why?
|
| Skin Care | 1 | 2020 | 15 | 0.720 |
Why?
|
| Endothelial Progenitor Cells | 2 | 2022 | 11 | 0.720 |
Why?
|
| Transplantation, Heterologous | 3 | 2012 | 1054 | 0.710 |
Why?
|
| Humans | 107 | 2024 | 270740 | 0.700 |
Why?
|
| Dermatologic Agents | 1 | 2020 | 44 | 0.690 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2020 | 127 | 0.690 |
Why?
|
| Debridement | 1 | 2020 | 121 | 0.680 |
Why?
|
| Emergency Treatment | 1 | 2020 | 104 | 0.670 |
Why?
|
| Time-to-Treatment | 2 | 2018 | 307 | 0.660 |
Why?
|
| Gastrostomy | 2 | 2020 | 196 | 0.650 |
Why?
|
| STAT3 Transcription Factor | 3 | 2022 | 1136 | 0.650 |
Why?
|
| Abdominal Wall | 1 | 2021 | 193 | 0.650 |
Why?
|
| Science | 1 | 2019 | 37 | 0.650 |
Why?
|
| Heart Defects, Congenital | 4 | 2024 | 1795 | 0.640 |
Why?
|
| Academies and Institutes | 1 | 2019 | 96 | 0.630 |
Why?
|
| Fetal Diseases | 8 | 2024 | 456 | 0.630 |
Why?
|
| Adenoviridae | 6 | 2015 | 1497 | 0.620 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 550 | 0.620 |
Why?
|
| Mice, Inbred C57BL | 19 | 2023 | 7100 | 0.620 |
Why?
|
| Cell Survival | 1 | 2024 | 3063 | 0.610 |
Why?
|
| Animals | 39 | 2024 | 61956 | 0.600 |
Why?
|
| Heart Transplantation | 1 | 2024 | 897 | 0.580 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 509 | 0.580 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 1051 | 0.570 |
Why?
|
| Disease Models, Animal | 9 | 2024 | 7381 | 0.570 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 317 | 0.570 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2019 | 477 | 0.560 |
Why?
|
| Mice | 31 | 2024 | 35600 | 0.560 |
Why?
|
| Retrospective Studies | 48 | 2024 | 39890 | 0.560 |
Why?
|
| Sacrococcygeal Region | 4 | 2024 | 44 | 0.560 |
Why?
|
| Female | 70 | 2024 | 148940 | 0.550 |
Why?
|
| Herniorrhaphy | 1 | 2018 | 179 | 0.550 |
Why?
|
| Angiopoietin-1 | 1 | 2015 | 20 | 0.510 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2015 | 217 | 0.500 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2022 | 1580 | 0.500 |
Why?
|
| Placental Insufficiency | 1 | 2015 | 13 | 0.500 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2015 | 105 | 0.490 |
Why?
|
| Pseudomonas Infections | 3 | 2022 | 166 | 0.480 |
Why?
|
| Length of Stay | 8 | 2024 | 2007 | 0.480 |
Why?
|
| Efficiency | 1 | 2015 | 93 | 0.480 |
Why?
|
| Pandemics | 2 | 2021 | 1610 | 0.470 |
Why?
|
| Placenta | 3 | 2023 | 561 | 0.470 |
Why?
|
| Myocardium | 1 | 2020 | 1232 | 0.460 |
Why?
|
| Cells, Cultured | 7 | 2024 | 5694 | 0.460 |
Why?
|
| Skin Physiological Phenomena | 2 | 2013 | 40 | 0.440 |
Why?
|
| Palate | 1 | 2013 | 24 | 0.440 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2013 | 6 | 0.440 |
Why?
|
| Gallbladder | 1 | 2013 | 68 | 0.440 |
Why?
|
| Cholecystitis | 1 | 2013 | 59 | 0.430 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 3 | 2022 | 20 | 0.430 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 231 | 0.430 |
Why?
|
| Fetal Growth Retardation | 1 | 2015 | 232 | 0.430 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2011 | 51 | 0.430 |
Why?
|
| Mouth Mucosa | 1 | 2013 | 224 | 0.410 |
Why?
|
| Infant | 19 | 2024 | 13999 | 0.410 |
Why?
|
| Pressure Ulcer | 1 | 2013 | 82 | 0.410 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 214 | 0.410 |
Why?
|
| Parvoviridae Infections | 1 | 2012 | 46 | 0.410 |
Why?
|
| Viral Tropism | 1 | 2012 | 41 | 0.410 |
Why?
|
| Saliva | 1 | 2013 | 238 | 0.400 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2013 | 192 | 0.380 |
Why?
|
| Viral Proteins | 1 | 2014 | 491 | 0.380 |
Why?
|
| Exocrine Glands | 1 | 2011 | 15 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 2400 | 0.370 |
Why?
|
| Research Personnel | 4 | 2022 | 167 | 0.370 |
Why?
|
| Cytomegalovirus | 1 | 2014 | 496 | 0.370 |
Why?
|
| United States | 9 | 2023 | 15861 | 0.360 |
Why?
|
| Child Development | 1 | 2013 | 266 | 0.360 |
Why?
|
| Postoperative Complications | 4 | 2020 | 5681 | 0.360 |
Why?
|
| Algorithms | 2 | 2022 | 3891 | 0.350 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2013 | 239 | 0.340 |
Why?
|
| Hymecromone | 2 | 2021 | 6 | 0.340 |
Why?
|
| Inflammation | 5 | 2024 | 2518 | 0.340 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 3949 | 0.340 |
Why?
|
| Keratinocytes | 3 | 2016 | 244 | 0.330 |
Why?
|
| Airway Obstruction | 2 | 2023 | 273 | 0.330 |
Why?
|
| Cytokines | 4 | 2024 | 2825 | 0.320 |
Why?
|
| Echocardiography | 3 | 2019 | 1228 | 0.300 |
Why?
|
| Endothelial Cells | 2 | 2024 | 1038 | 0.300 |
Why?
|
| Macrophages | 3 | 2024 | 1350 | 0.290 |
Why?
|
| Vagina | 2 | 2020 | 331 | 0.290 |
Why?
|
| Male | 32 | 2024 | 128315 | 0.290 |
Why?
|
| Clinical Competence | 1 | 2015 | 1325 | 0.280 |
Why?
|
| Stress, Mechanical | 2 | 2024 | 268 | 0.270 |
Why?
|
| Pneumonectomy | 2 | 2018 | 862 | 0.270 |
Why?
|
| Prenatal Care | 4 | 2023 | 349 | 0.270 |
Why?
|
| Pelvic Neoplasms | 2 | 2022 | 199 | 0.270 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2024 | 168 | 0.270 |
Why?
|
| Organ Culture Techniques | 3 | 2014 | 229 | 0.270 |
Why?
|
| Quality Improvement | 1 | 2013 | 914 | 0.260 |
Why?
|
| Immune Tolerance | 2 | 2019 | 427 | 0.250 |
Why?
|
| Alginates | 1 | 2024 | 22 | 0.240 |
Why?
|
| Hospitals, Pediatric | 3 | 2024 | 799 | 0.240 |
Why?
|
| Poloxamer | 1 | 2024 | 18 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2024 | 7895 | 0.240 |
Why?
|
| Porosity | 1 | 2024 | 59 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 1525 | 0.240 |
Why?
|
| Lymphatic Abnormalities | 1 | 2024 | 36 | 0.230 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2004 | 109 | 0.230 |
Why?
|
| Treatment Outcome | 16 | 2024 | 33737 | 0.230 |
Why?
|
| Monitoring, Intraoperative | 1 | 2005 | 264 | 0.220 |
Why?
|
| Organ Size | 5 | 2019 | 692 | 0.220 |
Why?
|
| Mice, SCID | 2 | 2021 | 1826 | 0.220 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2022 | 252 | 0.220 |
Why?
|
| Internship and Residency | 1 | 2015 | 1452 | 0.220 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 659 | 0.220 |
Why?
|
| LIM Domain Proteins | 1 | 2023 | 103 | 0.220 |
Why?
|
| Amniotic Band Syndrome | 1 | 2003 | 25 | 0.220 |
Why?
|
| Child | 14 | 2022 | 30559 | 0.220 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 288 | 0.210 |
Why?
|
| Academic Success | 1 | 2023 | 23 | 0.210 |
Why?
|
| Bronchi | 1 | 2005 | 325 | 0.210 |
Why?
|
| Hysterotomy | 2 | 2021 | 105 | 0.210 |
Why?
|
| Spinal Neoplasms | 2 | 2022 | 670 | 0.210 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 145 | 0.210 |
Why?
|
| Inovirus | 1 | 2022 | 3 | 0.210 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2024 | 183 | 0.210 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2024 | 312 | 0.210 |
Why?
|
| Signal Transduction | 2 | 2020 | 12103 | 0.210 |
Why?
|
| Cell Movement | 3 | 2015 | 2472 | 0.210 |
Why?
|
| Balloon Occlusion | 1 | 2022 | 60 | 0.210 |
Why?
|
| Hydronephrosis | 2 | 2013 | 51 | 0.200 |
Why?
|
| Limb Salvage | 1 | 2003 | 162 | 0.200 |
Why?
|
| Infant, Premature, Diseases | 1 | 2024 | 258 | 0.200 |
Why?
|
| Biofilms | 2 | 2022 | 204 | 0.200 |
Why?
|
| Polyhydramnios | 1 | 2021 | 51 | 0.190 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 5 | 1 | 2021 | 4 | 0.190 |
Why?
|
| Infant Mortality | 2 | 2020 | 178 | 0.190 |
Why?
|
| Transduction, Genetic | 2 | 2013 | 494 | 0.190 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 4960 | 0.190 |
Why?
|
| Cerebrospinal Fluid Leak | 2 | 2020 | 59 | 0.180 |
Why?
|
| Hemodynamics | 2 | 2022 | 949 | 0.180 |
Why?
|
| Adolescent | 10 | 2022 | 32767 | 0.180 |
Why?
|
| Ointments | 1 | 2020 | 23 | 0.180 |
Why?
|
| Wound Closure Techniques | 1 | 2020 | 32 | 0.180 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2020 | 29 | 0.180 |
Why?
|
| Simulation Training | 1 | 2022 | 162 | 0.180 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 89 | 0.180 |
Why?
|
| Fibrosis | 2 | 2021 | 733 | 0.170 |
Why?
|
| Surgical Wound | 1 | 2020 | 49 | 0.170 |
Why?
|
| Neck | 2 | 2024 | 395 | 0.170 |
Why?
|
| Mice, Knockout | 3 | 2015 | 5728 | 0.170 |
Why?
|
| Graft Rejection | 1 | 2024 | 847 | 0.170 |
Why?
|
| Child, Preschool | 7 | 2022 | 17061 | 0.170 |
Why?
|
| Animals, Newborn | 1 | 2024 | 1368 | 0.170 |
Why?
|
| Muscle Proteins | 1 | 2023 | 551 | 0.170 |
Why?
|
| Organ Specificity | 1 | 2021 | 737 | 0.170 |
Why?
|
| Multigene Family | 1 | 2021 | 469 | 0.170 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2021 | 141 | 0.160 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 431 | 0.160 |
Why?
|
| Pseudomonas Phages | 1 | 2019 | 11 | 0.160 |
Why?
|
| Haploinsufficiency | 1 | 2021 | 301 | 0.160 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 180 | 0.160 |
Why?
|
| Edema | 4 | 2023 | 262 | 0.160 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 5923 | 0.160 |
Why?
|
| Cohort Studies | 7 | 2021 | 9470 | 0.160 |
Why?
|
| Infant, Premature | 1 | 2024 | 844 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 1109 | 0.160 |
Why?
|
| Adaptation, Physiological | 2 | 2013 | 345 | 0.160 |
Why?
|
| Meningomyelocele | 1 | 2021 | 210 | 0.150 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2024 | 1002 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 714 | 0.150 |
Why?
|
| Fetal Tissue Transplantation | 2 | 2011 | 21 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2022 | 6764 | 0.150 |
Why?
|
| Abdomen | 1 | 2020 | 347 | 0.150 |
Why?
|
| Neurosurgical Procedures | 2 | 2020 | 633 | 0.150 |
Why?
|
| Uterus | 1 | 2003 | 798 | 0.150 |
Why?
|
| Hydrogels | 1 | 2019 | 134 | 0.150 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 1024 | 0.150 |
Why?
|
| Phagocytosis | 1 | 2019 | 292 | 0.150 |
Why?
|
| Regeneration | 1 | 2020 | 284 | 0.150 |
Why?
|
| Bleomycin | 1 | 2019 | 482 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 1281 | 0.150 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 661 | 0.150 |
Why?
|
| Oropharynx | 1 | 2017 | 80 | 0.140 |
Why?
|
| Financing, Government | 1 | 2017 | 37 | 0.140 |
Why?
|
| Insufflation | 1 | 2017 | 27 | 0.140 |
Why?
|
| Gynecology | 1 | 2019 | 235 | 0.140 |
Why?
|
| Heart Ventricles | 1 | 2022 | 847 | 0.140 |
Why?
|
| Faculty, Medical | 1 | 2020 | 313 | 0.140 |
Why?
|
| Glycosaminoglycans | 2 | 2021 | 71 | 0.140 |
Why?
|
| Career Choice | 1 | 2019 | 210 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 249 | 0.140 |
Why?
|
| Patient Selection | 2 | 2021 | 2025 | 0.140 |
Why?
|
| Neural Tube Defects | 1 | 2020 | 371 | 0.140 |
Why?
|
| Estrogens | 1 | 2020 | 805 | 0.140 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2016 | 96 | 0.130 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 1049 | 0.130 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 363 | 0.130 |
Why?
|
| Carbon Dioxide | 1 | 2017 | 328 | 0.130 |
Why?
|
| Telemedicine | 1 | 2022 | 552 | 0.130 |
Why?
|
| Anxiety | 1 | 2023 | 1240 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 379 | 0.130 |
Why?
|
| Disease Management | 1 | 2021 | 1090 | 0.120 |
Why?
|
| Liver | 4 | 2022 | 3086 | 0.120 |
Why?
|
| Thoracic Cavity | 1 | 2014 | 10 | 0.120 |
Why?
|
| Survival Rate | 6 | 2019 | 12541 | 0.120 |
Why?
|
| Allergens | 1 | 2017 | 252 | 0.120 |
Why?
|
| Lung Volume Measurements | 3 | 2023 | 97 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 608 | 0.120 |
Why?
|
| Transcriptome | 1 | 2023 | 1963 | 0.120 |
Why?
|
| Ultrasonography | 3 | 2013 | 1933 | 0.120 |
Why?
|
| Forecasting | 1 | 2017 | 702 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 223 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 901 | 0.110 |
Why?
|
| Time Factors | 3 | 2024 | 13006 | 0.110 |
Why?
|
| Interleukin-10 Receptor alpha Subunit | 1 | 2013 | 5 | 0.110 |
Why?
|
| Submandibular Gland | 1 | 2013 | 19 | 0.110 |
Why?
|
| Rabbits | 1 | 2015 | 1028 | 0.110 |
Why?
|
| Chylothorax | 1 | 2013 | 43 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 361 | 0.110 |
Why?
|
| Spinal Dysraphism | 1 | 2017 | 266 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 4372 | 0.110 |
Why?
|
| Torsion Abnormality | 1 | 2013 | 38 | 0.110 |
Why?
|
| Ovarian Diseases | 1 | 2013 | 51 | 0.110 |
Why?
|
| Flow Cytometry | 3 | 2015 | 3045 | 0.110 |
Why?
|
| Octreotide | 1 | 2013 | 131 | 0.110 |
Why?
|
| Depression | 1 | 2023 | 1730 | 0.110 |
Why?
|
| Biomarkers | 2 | 2015 | 5051 | 0.100 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 316 | 0.100 |
Why?
|
| Fetal Stem Cells | 1 | 2012 | 5 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 7655 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 705 | 0.100 |
Why?
|
| Adult | 14 | 2024 | 82040 | 0.100 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 1697 | 0.100 |
Why?
|
| Critical Illness | 1 | 2018 | 739 | 0.100 |
Why?
|
| Probability | 2 | 2024 | 886 | 0.100 |
Why?
|
| Survivors | 1 | 2018 | 1021 | 0.100 |
Why?
|
| Prognosis | 6 | 2024 | 22505 | 0.100 |
Why?
|
| Cell Nucleus | 2 | 2017 | 1712 | 0.100 |
Why?
|
| Pleural Effusion | 1 | 2013 | 228 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2013 | 255 | 0.100 |
Why?
|
| Growth Substances | 1 | 2012 | 326 | 0.090 |
Why?
|
| Mice, Inbred CFTR | 1 | 2011 | 3 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2020 | 7238 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 306 | 0.090 |
Why?
|
| Cecal Diseases | 1 | 2010 | 13 | 0.090 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 693 | 0.090 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2011 | 53 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 7783 | 0.090 |
Why?
|
| Hemangioblasts | 1 | 2010 | 2 | 0.090 |
Why?
|
| Laparoscopy | 1 | 2020 | 1302 | 0.090 |
Why?
|
| Appendix | 1 | 2010 | 45 | 0.090 |
Why?
|
| Postnatal Care | 3 | 2019 | 51 | 0.090 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2010 | 48 | 0.090 |
Why?
|
| Fetal Death | 2 | 2013 | 134 | 0.090 |
Why?
|
| Ohio | 3 | 2014 | 117 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2013 | 1642 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 131 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 401 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 4130 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 15218 | 0.080 |
Why?
|
| Wounds, Penetrating | 1 | 2010 | 157 | 0.080 |
Why?
|
| Immunity | 2 | 2022 | 354 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 1023 | 0.080 |
Why?
|
| Urogenital Abnormalities | 1 | 2011 | 174 | 0.080 |
Why?
|
| Heart | 1 | 2015 | 1195 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2013 | 618 | 0.080 |
Why?
|
| Hernia, Umbilical | 1 | 2008 | 44 | 0.080 |
Why?
|
| Hyaluronan Receptors | 2 | 2021 | 248 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 1286 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2010 | 2315 | 0.070 |
Why?
|
| Quality of Life | 2 | 2022 | 4761 | 0.070 |
Why?
|
| Young Adult | 6 | 2021 | 22251 | 0.070 |
Why?
|
| Hernia, Diaphragmatic | 3 | 2013 | 124 | 0.070 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2019 | 117 | 0.070 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2019 | 168 | 0.070 |
Why?
|
| Drainage | 1 | 2010 | 462 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2013 | 2033 | 0.070 |
Why?
|
| Crohn Disease | 1 | 2010 | 328 | 0.070 |
Why?
|
| Salivary Glands | 1 | 2007 | 139 | 0.070 |
Why?
|
| Ileum | 1 | 2007 | 167 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 451 | 0.070 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2005 | 8 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2013 | 2250 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 3 | 2017 | 2454 | 0.060 |
Why?
|
| Pregnancy Outcome | 3 | 2017 | 684 | 0.060 |
Why?
|
| Texas | 3 | 2024 | 6449 | 0.060 |
Why?
|
| Granulation Tissue | 1 | 2005 | 26 | 0.060 |
Why?
|
| Anesthesia, Epidural | 1 | 2005 | 32 | 0.060 |
Why?
|
| Parenteral Nutrition, Total | 2 | 2017 | 139 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2013 | 4942 | 0.060 |
Why?
|
| Physicians | 1 | 2013 | 854 | 0.060 |
Why?
|
| Sclerotherapy | 1 | 2024 | 53 | 0.060 |
Why?
|
| Streptozocin | 1 | 2004 | 70 | 0.060 |
Why?
|
| Surface-Active Agents | 1 | 2024 | 41 | 0.060 |
Why?
|
| Fentanyl | 1 | 2005 | 153 | 0.060 |
Why?
|
| Wrist | 1 | 2003 | 28 | 0.060 |
Why?
|
| Lentivirus | 1 | 2004 | 164 | 0.050 |
Why?
|
| Airway Management | 1 | 2024 | 113 | 0.050 |
Why?
|
| Mice, Mutant Strains | 2 | 2019 | 655 | 0.050 |
Why?
|
| Dendritic Cells | 2 | 2021 | 1110 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2022 | 53 | 0.050 |
Why?
|
| Pseudomonas | 1 | 2022 | 22 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2005 | 822 | 0.050 |
Why?
|
| Models, Animal | 2 | 2020 | 657 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 4492 | 0.050 |
Why?
|
| Universities | 1 | 2023 | 160 | 0.050 |
Why?
|
| Propylene Glycol | 1 | 2021 | 9 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 896 | 0.050 |
Why?
|
| Incidence | 3 | 2019 | 5824 | 0.050 |
Why?
|
| Antithrombin III | 1 | 2021 | 30 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2022 | 255 | 0.050 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2021 | 11 | 0.050 |
Why?
|
| Disaccharides | 1 | 2021 | 30 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2021 | 141 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 99 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 87 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2005 | 565 | 0.050 |
Why?
|
| Social Class | 1 | 2023 | 324 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 1105 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2024 | 359 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2022 | 322 | 0.050 |
Why?
|
| Apoptosis | 1 | 2015 | 7757 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 369 | 0.040 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2021 | 88 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1379 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 151 | 0.040 |
Why?
|
| Diaphragm | 1 | 2021 | 187 | 0.040 |
Why?
|
| Thorax | 1 | 2021 | 229 | 0.040 |
Why?
|
| Sirolimus | 1 | 2024 | 831 | 0.040 |
Why?
|
| Patient Preference | 1 | 2022 | 229 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2024 | 469 | 0.040 |
Why?
|
| Ethanol | 1 | 2021 | 272 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2019 | 73 | 0.040 |
Why?
|
| Counseling | 1 | 2022 | 381 | 0.040 |
Why?
|
| Immune System | 1 | 2021 | 275 | 0.040 |
Why?
|
| Mast Cells | 1 | 2021 | 229 | 0.040 |
Why?
|
| Water | 1 | 2021 | 386 | 0.040 |
Why?
|
| Heparin | 1 | 2021 | 342 | 0.040 |
Why?
|
| Mothers | 1 | 2023 | 416 | 0.040 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2019 | 25 | 0.040 |
Why?
|
| Resuscitation | 1 | 2022 | 274 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2019 | 97 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 1076 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2022 | 658 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2024 | 1234 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 657 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 318 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 5162 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 831 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2020 | 259 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 100 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2021 | 445 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 299 | 0.040 |
Why?
|
| Perinatal Mortality | 1 | 2017 | 42 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 4147 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2019 | 262 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 2057 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 2220 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 727 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 699 | 0.040 |
Why?
|
| Sulfhydryl Compounds | 1 | 2017 | 70 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2019 | 391 | 0.030 |
Why?
|
| Psychometrics | 1 | 2022 | 973 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2017 | 116 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2022 | 931 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2019 | 1121 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 15927 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2022 | 13414 | 0.030 |
Why?
|
| Endoscopy | 1 | 2019 | 496 | 0.030 |
Why?
|
| Half-Life | 1 | 2016 | 269 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2017 | 167 | 0.030 |
Why?
|
| Biological Availability | 1 | 2016 | 225 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 775 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 1580 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 692 | 0.030 |
Why?
|
| Stents | 1 | 2022 | 999 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 1424 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 399 | 0.030 |
Why?
|
| Age Factors | 2 | 2018 | 5457 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 1432 | 0.030 |
Why?
|
| Protein Transport | 1 | 2017 | 737 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 1174 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 917 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 1412 | 0.030 |
Why?
|
| Thoracostomy | 1 | 2013 | 47 | 0.030 |
Why?
|
| Cardiac Output, High | 1 | 2013 | 3 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 1584 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 432 | 0.030 |
Why?
|
| Recurrence | 1 | 2021 | 4878 | 0.030 |
Why?
|
| Chest Tubes | 1 | 2013 | 119 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 968 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 1608 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 1301 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 3187 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2017 | 4116 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2013 | 219 | 0.020 |
Why?
|
| Middle Aged | 2 | 2021 | 90352 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3035 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 6177 | 0.020 |
Why?
|
| Tidal Volume | 1 | 2011 | 58 | 0.020 |
Why?
|
| Vomiting | 1 | 2013 | 361 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 1248 | 0.020 |
Why?
|
| Nausea | 1 | 2013 | 539 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2013 | 9292 | 0.020 |
Why?
|
| Pneumonia | 1 | 2017 | 796 | 0.020 |
Why?
|
| Urinary Tract | 1 | 2011 | 86 | 0.020 |
Why?
|
| Benzylamines | 1 | 2010 | 98 | 0.020 |
Why?
|
| Hospital Records | 1 | 2010 | 9 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2013 | 378 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2017 | 1563 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2010 | 117 | 0.020 |
Why?
|
| Soft Tissue Injuries | 1 | 2010 | 48 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 563 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2010 | 96 | 0.020 |
Why?
|
| Risk Factors | 2 | 2019 | 17888 | 0.020 |
Why?
|
| Ovary | 1 | 2013 | 688 | 0.020 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2010 | 108 | 0.020 |
Why?
|
| Soft Tissue Infections | 1 | 2010 | 93 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 4223 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 1986 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 418 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2010 | 276 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2010 | 244 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 984 | 0.020 |
Why?
|
| Microvilli | 1 | 2007 | 88 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2007 | 279 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 347 | 0.020 |
Why?
|
| Transgenes | 1 | 2007 | 576 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 439 | 0.020 |
Why?
|
| Tobramycin | 1 | 2005 | 25 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 1407 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2008 | 585 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 1189 | 0.020 |
Why?
|
| Bupivacaine | 1 | 2005 | 73 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2005 | 91 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 2090 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2005 | 258 | 0.010 |
Why?
|
| Acute Disease | 1 | 2010 | 2493 | 0.010 |
Why?
|
| Comorbidity | 1 | 2011 | 2394 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 3597 | 0.010 |
Why?
|
| Thoracotomy | 1 | 2005 | 218 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2005 | 178 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2005 | 404 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 633 | 0.010 |
Why?
|
| Disease Progression | 1 | 2014 | 6867 | 0.010 |
Why?
|
| Analgesics | 1 | 2005 | 408 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 3339 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 9039 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 6390 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2005 | 1516 | 0.010 |
Why?
|
| Aged | 1 | 2003 | 73333 | 0.010 |
Why?
|
| Pain | 1 | 2005 | 1694 | 0.010 |
Why?
|